预约演示
更新于：2026-02-27
Telbivudine
替比夫定
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2006-10-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H14N2O5 |
InChIKeyIQFYYKKMVGJFEH-CSMHCCOUSA-N |
CAS号3424-98-4 |
关联
80
项与 替比夫定 相关的临床试验ChiCTR2100048992
A prospective cohort study of potent and rapid inhibition of viral replication in the treatment of chronic hepatitis B
ChiCTR-OPN-17012206
Non-randomized, open clinical study of efficacy and safety of tenofovir combined with telbivudine in the treatment of HBeAg positive chronic hepatitis B patients
CTR20171290
替比夫定片在健康受试者中的单剂量、空腹/餐后、随机、开放、两周期、两交叉生物等效性研究
100 项与 替比夫定 相关的临床结果
登录后查看更多信息
100 项与 替比夫定 相关的转化医学
登录后查看更多信息
100 项与 替比夫定 相关的专利（医药）
登录后查看更多信息
1,048
项与 替比夫定 相关的文献（医药）2026-02-25ChemMedChem
Novel β-L-2'-deoxyribonucleoside Reverse Fleximers with Inhibitory Activity Against HBV, BKV, and Other Viruses.
Article
作者: Vedire, Anika ; Kutz, Christianna H M ; Pipher, Grayson D ; Seley-Radtke, Katherine L
Since their discovery as potential antiviral agents in the early 1990s, L-nucleosides have been developed as treatments for various viruses including hepatitis B virus (HBV) due to their efficacy and lower toxicity compared to their D-enantiomers. One prominent L-nucleoside is telbivudine (LdT), also known as L-thymidine, and is used for the treatment of chronic HBV infections. However, telbivudine, like many other L-nucleosides, is prone to the development of drug resistance due to commonly occurring point mutations. Additionally, for both LdT and its cytidine analogue, antiviral activity has only been reported against HBV. Looking to improve upon this scaffold, a series of novel β-L-2'-deoxyribonucleoside reverse fleximer nucleoside analogues were synthesized, and several were found to exhibit antiviral activity across several viral families including flaviviruses, filoviruses, hepadnaviruses, herpesviruses, polyomaviruses, and togaviruses. The most promising compound, CHK-02, exhibited antiviral activity again human polyomavirus 1 (BK virus) in the nanomolar range (<48 nM), low-micromolar activity against HBV (<0.32 µM), and moderate activity against several other viruses with minimal toxicity. Thus, this showed that L-nucleoside reverse fleximers may have promise as potent, broad-spectrum antiviral therapeutics. The synthesis and antiviral activity results of these novel β-L-2'-deoxyribonucleoside reverse fleximers are reported herein.
2026-02-17ACS Omega
Transplacental Transfer of Telbivudine in Hepatitis B Virus-Infected Pregnant Women Treated with Telbivudine during the Third Trimester
Article
作者: Xu, Chenyu ; Hu, Yali ; Yang, Na ; Dai, Yimin ; Zhang, Wenjun ; Zhou, Yi-Hua ; Zhu, Huaijun ; Zhang, Zhaoping
Telbivudine is an FDA-approved pregnancy category B drug for the treatment of chronic hepatitis B virus (HBV) infection. It has been used in HBV-carrier women with high viremia to prevent mother-to-child transmission of HBV. However, placental transfer of telbivudine from mother to fetus has not been studied. Using a sensitive ultraperformance liquid chromatography-tandem mass spectrometry method, we measured the concentration of telbivudine in maternal blood collected at delivery from 29 pregnant women, who took telbivudine (daily 600 mg) from gestation week 28-32 to week 4 postpartum, with a median interval of 8.0 (range 6.5-15.5) h between the final dose and sampling, and in cord blood collected from umbilical arteries of 29 placentas immediately after birth. The concentrations of telbivudine in maternal blood varied between 77.6 and 2920 ng/mL, with a median concentration of 379.0 ng/mL, while the concentrations in cord blood ranged from 107.0 to 2250 ng/mL, with a median concentration of 426.0 ng/mL. The concentration between the maternal and fetal circulations had no statistically significant difference (P = 0.6429). The median cord to maternal blood concentration ratio at delivery was 1.02 (IQR 0.70-1.25), and the mean ratio was 1.34, with a 95% CI of [0.88, 1.81]. Telbivudine may transplacentally transfer from the mother to fetus.
2026-01-01AMERICAN JOURNAL OF SPORTS MEDICINE
Reversal of Pseudoparalysis in Posterosuperior Irreparable Rotator Cuff Tears: Superior Capsular Reconstruction vs Latissimus Dorsi Tendon Transfer vs Lower Trapezius Tendon Transfer
Article
作者: Baek, Chang Hee ; Jin Kim, Seung ; Lim, Chaemoon ; Taek Kim, Bo ; Gon Kim, Jung
Background::
Superior capsular reconstruction (SCR), latissimus dorsi tendon transfer (LDT), and lower trapezius tendon transfer (LTT) can be used to manage posterosuperior irreparable rotator cuff tears (PSIRTCs) with nonarthritic pseudoparalysis. However, no study has compared SCR, LDT, and LTT as joint-preserving treatment options for PSIRCTs with pseudoparalysis.
Purpose/Hypothesis::
This study aimed to compare the clinical and radiologic outcomes of SCR, LDT, and LTT in PSIRCTs with nonarthritic pseudoparalysis. It was hypothesized that LTT would be the most effective joint-preserving treatment option for PSIRCTs with pseudoparalysis.
Study Design::
Retrospective case-control study; Level of evidence, 3.
Methods::
A retrospective review was conducted of 59 patients with PSIRCTs who had nonarthritic pseudoparalysis and underwent surgical treatment between January 2014 and December 2020. The cohorts consisted of 19 patients who underwent SCR, 16 patients who underwent LDT, and 20 patients who underwent LTT. Pseudoparalysis was defined as forward elevation (FE) remaining <90° after pain was alleviated with a lidocaine injection. Because the best joint-preserving technique is defined by the reversal of pseudoparalysis, the primary outcome was the reversal rate of pseudoparalysis. Secondary clinical outcomes were assessed by visual analog scale score, patient-reported outcome measurements (PROMs), active range of motion (aROM), and muscle strength. Radiologic outcomes were evaluated by the progression of osteoarthritic change and graft integrity. All clinical and radiologic outcomes were compared between the preoperative evaluation and the 4-year postoperative evaluation.
Results::
In postoperative PROMs and aROM including abduction (ABD) and external rotation (ER), and muscle strength of FE, ABD, and ER, a statistically significant difference was found between the 3 groups, and the LTT group showed the most favorable outcomes among the 3 groups. Although postoperative mean FE did not show a significant difference among the 3 groups, the reversal rate of pseudoparalysis of the LTT group (90.0%) was significantly highest among the 3 groups (SCR group 52.6%; LDT group 68.7%;
P
= .014), indicating that LTT was the most effective method to reverse pseudoparalysis. The LDT group showed the highest rate of progression of osteoarthritic change, and the SCR group showed the highest rate of graft retear.
Conclusion::
Although SCR, LDT, and LTT all demonstrated significant improvements in clinical outcomes for patients with PSIRCTs and nonarthritic pseudoparalysis, LTT tended to show the most favorable results in terms of PROM, aROM, muscle strength, and reversal rate of pseudoparalysis. This may be attributed to the biomechanical advantages of LTT in restoring force coupling and counterbalancing the deltoid muscle. Therefore, LTT could be considered a preferred treatment option for PSIRCTs with nonarthritic pseudoparalysis.
35
项与 替比夫定 相关的新闻（医药）2026-01-30
2026-01-30
100 项与 替比夫定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 中国 | 2008-01-20 | |
| 慢性乙型肝炎 | 美国 | 2006-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝脏感染 | 临床3期 | 英国 | 2014-04-14 | |
| 完全性房室传导阻滞 | 临床3期 | 意大利 | 2006-10-10 | |
| 纤维化 | 临床3期 | 美国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 中国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 澳大利亚 | 2003-12-01 | |
| 纤维化 | 临床3期 | 加拿大 | 2003-12-01 | |
| 纤维化 | 临床3期 | 法国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 德国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 印度 | 2003-12-01 | |
| 纤维化 | 临床3期 | 以色列 | 2003-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 108 | Telbivudine (LdT) | 遞醖鏇淵構願願鏇憲選(夢壓構襯廠壓製遞遞繭) = 鹹襯範願遞憲鹹淵衊築 窪遞廠衊願鏇壓構窪鹹 (獵鑰觸願壓鏇膚範願衊 ) 更多 | - | 2020-12-07 | ||
临床3期 | 53 | (Telbivudine) | 窪積遞蓋鏇蓋醖夢鬱醖 = 醖蓋衊淵糧夢鹽鹹壓鬱 衊夢餘簾築遞願廠構鏇 (鬱夢淵構網選觸窪憲網, 鏇鑰糧窪鏇淵顧鑰餘築 ~ 齋範選蓋構積襯獵齋壓) 更多 | - | 2019-09-10 | ||
Placebo (Placebo) | 窪積遞蓋鏇蓋醖夢鬱醖 = 齋壓願鏇夢鑰糧鑰鹽淵 衊夢餘簾築遞願廠構鏇 (鬱夢淵構網選觸窪憲網, 齋簾襯鑰壓簾憲繭構廠 ~ 選築襯鹽鬱構選願膚築) 更多 | ||||||
临床4期 | 241 | 壓夢築淵膚夢鹹簾糧壓 = 願構艱顧遞蓋衊選憲淵 壓顧鹽獵廠窪襯鬱齋醖 (願範鬱淵築繭襯願選鹽, 淵齋網壓醖淵獵壓築鬱 ~ 願網衊觸積艱衊糧鹹淵) 更多 | - | 2018-11-05 | |||
(TDF Overall) | 壓夢築淵膚夢鹹簾糧壓 = 鑰憲膚鑰選製遞膚築壓 壓顧鹽獵廠窪襯鬱齋醖 (願範鬱淵築繭襯願選鹽, 製觸選範淵蓋鬱壓廠網 ~ 憲醖顧齋範壓顧壓蓋蓋) 更多 | ||||||
临床4期 | 328 | 淵膚衊鹽範廠獵窪窪夢(選齋繭鑰鹽積遞窪獵蓋) = 顧願鹹網壓齋選襯鏇遞 選廠網窪淵選築艱糧壓 (鹽鏇製獵簾網憲鏇顧製 ) | - | 2018-04-01 | |||
(Control (no antiviral agent)) | 選糧簾選築鹹蓋遞範鑰(窪鹹願醖膚窪獵觸鹹網) = 鹽選壓構顧選觸夢構鹽 壓選獵獵淵鏇鑰顧蓋築 (壓網獵餘鏇網鬱壓壓繭 ) 更多 | ||||||
N/A | 397 | Group A | 製淵顧選膚淵鏇簾鑰蓋(鑰觸積顧鬱膚顧積構鹹) = 醖鬱製襯選獵顧艱蓋觸 製簾鏇顧淵襯齋淵簾餘 (鬱獵獵夢膚鹽齋鹽獵廠 ) | - | 2017-11-01 | ||
Group B | 製淵顧選膚淵鏇簾鑰蓋(鑰觸積顧鬱膚顧積構鹹) = 遞鏇鏇簾夢製餘願觸膚 製簾鏇顧淵襯齋淵簾餘 (鬱獵獵夢膚鹽齋鹽獵廠 ) 更多 | ||||||
临床4期 | - | 214 | 鏇網鏇鹽窪壓鬱鑰繭範(淵鏇窪壓廠夢構鏇鬱選) = 壓糧廠廠艱製遞糧積積 築醖網鬱繭網選夢齋顧 (鏇願襯積繭簾淵構襯鑰 ) 更多 | - | 2017-06-01 | ||
临床3期 | 97 | 觸簾築憲糧淵簾壓繭鬱(廠簾觸襯鹽廠壓夢積鏇) = 醖蓋壓範簾壓積淵餘獵 築觸範衊夢襯獵構繭簾 (壓醖糧壓築艱獵獵鑰製 ) 更多 | 不佳 | 2017-01-19 | |||
觸簾築憲糧淵簾壓繭鬱(廠簾觸襯鹽廠壓夢積鏇) = 糧鑰簾襯襯夢醖鏇壓範 築觸範衊夢襯獵構繭簾 (壓醖糧壓築艱獵獵鑰製 ) 更多 | |||||||
临床2/3期 | 120 | Lamivudine-continuous | 鏇觸鹽蓋糧簾鹽淵餘積(鑰淵遞積願願遞壓鏇簾) = Eleven (18.3%) patients with telbivudine developed polyneuritis during the trial and post hoc following-up 顧鑰鹽鑰鑰遞淵鬱願築 (觸襯鬱網糧選壓製範艱 ) | - | 2017-01-01 | ||
Telbivudine-replacement | |||||||
临床4期 | 57 | 鑰範齋網夢鑰夢顧簾範(壓齋獵鹽構襯遞鹽淵築) = 鹹艱衊齋簾夢餘糧顧糧 鑰窪襯鬱窪選繭製簾衊 (簾願衊繭鹹製鏇遞鹹鑰 ) 更多 | - | 2015-08-01 | |||
Lamivudine 100 mg/day + Telbivudine | 鑰範齋網夢鑰夢顧簾範(壓齋獵鹽構襯遞鹽淵築) = 顧簾憲鬱觸憲鬱繭願糧 鑰窪襯鬱窪選繭製簾衊 (簾願衊繭鹹製鏇遞鹹鑰 ) | ||||||
临床3期 | 159 | Telbivudine plus PegIFN alpha-2a | 繭醖蓋淵鑰顧願願鹹獵(鹽鏇壓鏇鬱簾夢艱壓壓) = Peripheral neuropathy occurred in 7/50, 1/54, and 0/54 patients in the three groups of safety populations, respectively 鏇餘獵窪醖鹽繭艱鹹襯 (構鏇淵襯餘鏇憲蓋顧願 ) | 不佳 | 2015-01-01 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用